HIVMA Recognizes Excellence in HIV Clinical Education and Research With 2022 Awards

HIVMA honors David Spach, MD and Sara Bares, MD for contributions to HIV clinical education and research.

IDSA Statement on Global Fund Replenishment

IDSA and HIVMA are pleased that global efforts to end the HIV, tuberculosis and malaria epidemics received much needed investment at the seventh replenishment of the Global Fund to Fight AIDS, Tuberculosis and Malaria.

Protecting Patient Autonomy and the Provider-Patient Relationship

IDSA and HIVMA strongly oppose government interference in the patient-health care provider relationship and religious refusal laws and regulations that allow health care professionals, employers, systems or insurers to deny access to services based on their own personal religious beliefs.

Denial of Coverage for PrEP is Dangerous and Unacceptable

HIVMA is deeply disturbed by today’s ruling by a U.S. District Court judge that allows employers in Texas to deny health care coverage for HIV pre-exposure prophylaxis — a highly effective biomedical intervention for preventing HIV infection.

HIVMA Applauds Federal Implementation Plan to End HIV Epidemic, Calls for Workforce Summit and Appropriate Congressional Funding

HIVMA welcomes the release of the comprehensive National HIV/AIDS Strategy Federal Implementation Plan that provides an important road map for reducing new HIV infections by 90% by 2030.

Statement on NIAID Director Anthony Fauci

IDSA and HIVMA are immensely grateful for Dr. Anthony Fauci’s contributions to the identification, treatment and containment of infectious diseases through his 38 years of leadership of the National Institute of Allergy and Infectious Diseases.

HIV Providers Call for Policy Reforms to End HIV as an Epidemic

IDSA and HIVMA say that while barriers to ending the HIV epidemic are significant, the goal could be within reach with broad-based policy reforms at the federal, state and local levels.

Monkeypox Bill Provides Crucial Steps Toward Equitable Access to Testing

IDSA applauds new legislation introduced by Rep. Sean Patrick Maloney (D-NY) to ensure monkeypox testing is available at no cost to the public.

Monkeypox Public Health Emergency Should Grant Flexibility to Expand Treatment and Vaccine Access

IDSA and HIVMA support the Biden Administration’s decision to declare the monkeypox outbreak a public health emergency.

IDSA and HIVMA Applaud New Administration Monkeypox Coordinators, Call for Funding and Improved Vaccine Supply and Access

As monkeypox cases top more than 5,800 across 48 states, there is no time to waste.

IDSA Statement on Increase in Monkeypox Vaccine Supply

Today’s U.S. Department of Health and Human Services announcement that nearly 800,000 additional doses of the monkeypox vaccine are now available for distribution is a welcome development, but much more is urgently needed.

IDSA/HIVMA Support Rapid CDC Response to Monkeypox Treatment Access Issues

IDSA and HIVMA appreciate the CDC’s swift action in responding to health care provider concerns regarding the significant procedural barriers required to obtain tecovirimat, or TPOXX, through the Expanded Access for Investigational New Drug program.